In­cyte nabs 2nd ever ap­proval ahead of sched­ule as FDA in­sists it can still re­view on time

Al­most a full year af­ter In­cyte broke off a trou­bled part­ner­ship with Eli Lil­ly to fo­cus on its own in­ter­nal en­gine, one of the drugs from that en­gine will en­ter the mar­ket.

Pemi­ga­tinib, now brand­ed as Pe­mazyre, ob­tained FDA ap­proval as a sec­ond-line treat­ment for a rare form of can­cer known as cholan­gio­car­ci­no­ma, or bile duct can­cer. For In­cyte, a biotech that rose to promi­nence on the strength of a sin­gle drug — Jakafi — and a slew of Big Phar­ma part­ner­ships, the ap­proval marks the first of what they hope will be a se­ries of in­ter­nal suc­cess­es and the first sign of a new phase for the com­pa­ny, al­beit one that is un­like­ly to make a huge com­mer­cial splash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.